Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hepato-Biliary-Pancreatic Sciences
Published in: Journal of Hepato-Biliary-Pancreatic Sciences 2/2010

01-03-2010 | Review Article

Significance of mucin expression in pancreatobiliary neoplasms

Authors: Suguru Yonezawa, Michiyo Higashi, Norishige Yamada, Seiya Yokoyama, Masamichi Goto

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 2/2010

Login to get access

Abstract

Mucins are high molecular weight glycoproteins that play important roles in carcinogenesis and tumor invasion. We have described, for the first time, that pancreatic ductal adenocarcinomas (PDACs) with an aggressive behavior and a poor outcome expressed MUC1 (pan-epithelial membrane-associated mucin) but did not express MUC2 (intestinal-type secreted mucin), whereas intraductal papillary mucinous neoplasms (IPMNs) with indolent behavior and a favorable outcome did not express MUC1 but did express MUC2. These expression profiles of MUC1 and MUC2 related to the prognoses of the patients were also observed in biliary neoplasms such as intrahepatic cholangiocarcinoma (ICC)-mass-forming type (MF), mucin-producing bile duct tumor (MPBT), and extrahepatic bile duct carcinoma (EHBDC). We also found recently that high expression of MUC4 (tracheobronchial membrane-associated mucin) in PDACs, ICCs-MF, and EHBDCs was a new independent poor prognostic factor, although MUC4 was not expressed in normal pancreatobiliary tissue. High de novo expression of MUC5AC (gastric-type secreted mucin) was observed in many types of pancreatobiliary neoplasms, including all grades of pancreatic intraepithelial neoplasia (PanIN) and biliary intraepithelial neoplasia (BilIN), and all types of IPMNs and MPBTs, as well as PDACs and ICCs-MF, although MUC5AC was not expressed in normal pancreatobiliary tissue. The combined status of MUC1, MUC2, MUC4, and MUC5AC expression may be useful for the early detection of pancreatobiliary neoplasms and evaluation of their malignancy. In regard to the mechanism of mucin expression, we have recently reported that MUC1, MUC2, MUC4, and MUC5AC gene expression is regulated by epigenetics (DNA methylation and histone H3 lysine 9 modification) in cancer cell lines, including PDAC cells. Translational research of mucin gene expression mechanisms, including epigenetics, in pancreatobiliary neoplasms may give us new tools for the early and accurate detection of these neoplasms.
Literature
1.
2.
Isaji S, Kawarada Y, Uemoto S. Classification of pancreatic cancer: comparison of Japanese and UICC classifications. Pancreas. 2004;28:231–4.CrossRefPubMed
3.
Ishikawa O, Ohigashi H, Imaoka S, Nakaizumi A, Uehara H, Kitamura T, et al. Minute carcinoma of the pancreas measuring 1 cm or less in diameter—collective review of Japanese case reports. Hepatogastroenterology. 1999;46:8–15.PubMed
4.
Egawa S, Takeda K, Fukuyama S, Motoi F, Sunamura M, Matsuno S. Clinicopathological aspects of small pancreatic cancer. Pancreas. 2004;28:235–40.CrossRefPubMed
5.
Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery. 2000;127:498–505.CrossRefPubMed
6.
Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg. 2002;89:1525–31.CrossRefPubMed
7.
Wade TP, Prasad CN, Virgo KS, Johnson FE. Experience with distal bile duct cancers in US. Veterans affairs hospitals: 1987–1991. J Surg Oncol. 1997;64:242–5.CrossRefPubMed
8.
Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg. 1996;83:1712–5.CrossRefPubMed
9.
Ouchi K, Matsuno S, Sato T. Long-term survival in carcinoma of the biliary tract. Analysis of prognostic factors in 146 resections. Arch Surg. 1989;124:248–52.PubMed
10.
Hamilton SR, Aaltonen LA. Pathology and genetics of tumours of the digestive system: 8 tumours of the liver and intrahepatic bile ducts, p. 157–99; 10 Tumours of the exocrine pancreas, p. 219–50. Lyon: IARC; 2000.
11.
Shibahara H, Tamada S, Goto M, Oda K, Nagino M, Nagasaka T, et al. Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary–mucinous neoplasms. Am J Surg Pathol. 2004;28:327–38.CrossRefPubMed
12.
Zen Y, Fujii T, Itatsu K, Nakamura K, Minato H, Kasashima S, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology. 2006;44:1333–43.CrossRefPubMed
13.
Takaori K. Current understanding of precursors to pancreatic cancer. J Hepatobiliary Pancreat Surg. 2007;14:217–23.CrossRefPubMed
14.
Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579–86.CrossRefPubMed
15.
Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977–87.CrossRefPubMed
16.
Zen Y, Adsay NV, Bardadin K, Colombari R, Ferrell L, Haga H, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol. 2007;20:701–9.CrossRefPubMed
17.
Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surfaces. Nat Rev Cancer. 2004;4:45–60.CrossRefPubMed
18.
Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int. 1997;47:813–30.CrossRefPubMed
19.
Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics. 2008;8:3329–41.CrossRefPubMed
20.
Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA. 1989;86:9891–5.CrossRefPubMed
21.
Chen Y, Zhao YH, Kalaslavadi TB, Hamati E, Nehrke K, Le AD, et al. Genome-wide search and identification of a novel gel-forming mucin MUC19/Muc19 in glandular tissues. Am J Respir Cell Mol Biol. 2004;30:155–65.CrossRefPubMed
22.
Higuchi T, Orita T, Nakanishi S, Katsuya K, Watanabe H, Yamasaki Y, et al. Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J Biol Chem. 2004;279:1968–79.CrossRefPubMed
23.
Itoh Y, Kamata-Sakurai M, Denda-Nagai K, Nagai S, Tsuiji M, Ishii-Schrade K, et al. Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin. Glycobiology. 2008;18:74–83.CrossRefPubMed
24.
Moniaux N, Escande F, Porchet N, Aubert JP, Batra SK. Structural organization and classification of the human mucin genes. Front Biosci. 2001;6:D1192–206.CrossRefPubMed
25.
Osako M, Yonezawa S, Siddiki B, Huang J, Ho JJ, Kim YS, et al. Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer. 1993;71:2191–9.CrossRefPubMed
26.
Yamashita K, Yonezawa S, Tanaka S, Shirahama H, Sakoda K, Imai K, et al. Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. Int J Cancer. 1993;55:82–91.CrossRefPubMed
27.
Kitamura H, Yonezawa S, Tanaka S, Kim YS, Sato E. Expression of mucin carbohydrates and core proteins in carcinomas of the ampulla of Vater: their relationship to prognosis. Jpn J Cancer Res. 1996;87:631–40.PubMed
28.
Yonezawa S, Sueyoshi K, Nomoto M, Kitamura H, Nagata K, Arimura Y, et al. MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: its close relationship with prognosis of the patients. Hum Pathol. 1997;28:344–52.CrossRefPubMed
29.
Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS, et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology. 1999;30:1347–55.CrossRefPubMed
30.
Yonezawa S, Nakamura A, Horinouchi M, Sato E. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg. 2002;9:328–41.CrossRefPubMed
31.
Nakamura A, Horinouchi M, Goto M, Nagata K, Sakoda K, Takao S, et al. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol. 2002;197:201–10.CrossRefPubMed
32.
Horinouchi M, Nagata K, Nakamura A, Goto M, Takao S, Sakamoto M, et al. Expression of different glycoforms of membrane mucin (MUC1) and secretory mucin (MUC2, MUC5AC and MUC6) in pancreatic neoplasms. Acta Histochem Cytochem. 2003;36:443–53.CrossRef
33.
Tamada S, Goto M, Nomoto M, Nagata K, Shimizu T, Tanaka S, et al. Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol Int. 2002;52:713–23.CrossRefPubMed
34.
Yonezawa S, Higashi M, Yamada N, Goto M. Precursor lesions of pancreatic cancer. Gut and Liver. 2008;2:137–54.CrossRef
35.
Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA. Cell signaling through membrane mucins. Bioessays. 2003;25:66–71.CrossRefPubMed
36.
Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology. 2004;39:220–9.CrossRefPubMed
37.
Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T, et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol. 2005;58:845–52.CrossRefPubMed
38.
Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, Imai K, et al. MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res. 2006;12:4257–64.CrossRefPubMed
39.
Nagata K, Horinouchi M, Saitou M, Higashi M, Nomoto M, Goto M, et al. Mucins expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg. 2007;14:243–54.CrossRefPubMed
40.
Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002;123:1052–60.CrossRefPubMed
41.
Zen Y, Sasaki M, Fujii T, Chen TC, Chen MF, Yeh TS, et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct—an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol. 2006;44:249–50.CrossRef
42.
Yamada N, Nishida Y, Tsutsumida H, Hamada T, Goto M, Higashi M, et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res. 2008;68:2708–16.CrossRefPubMed
43.
Hamada T, Goto M, Tsutsumida H, Nomoto M, Higashi M, Sugai T, et al. Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing. Cancer Lett. 2005;227:175–84.CrossRefPubMed
44.
Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M, et al. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer. 2006;119:1850–7.CrossRefPubMed
45.
Yamada N, Nishida Y, Tsutsumida H, Goto M, Higashi M, Nomoto M, et al. Promoter CpG methylation in cancer cells contributes to regulation of MUC4. Br J Cancer. 2009;100:344–51.CrossRefPubMed
46.
Yamada N, Yokoyama S, Nishida Y, Houjou I, Tsutsumida H, Goto M, et al. CpG methylation in the distal region of MUC5AC promoter contributes to the regulation of MUC5AC. Abstract in 68th annual meeting of the Japanese Cancer Society, Yokohama, 1–3 Oct 2009.
47.
Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol. 2002;117:791–6.CrossRefPubMed
48.
Park HU, Kim JW, Kim GE, Bae HI, Crawley SC, Yang SC, et al. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas. 2003;26:e48–54.CrossRefPubMed
49.
Lüttges J, Zamboni G, Longnecker D, Klöppel G. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol. 2001;25:942–8.CrossRefPubMed
50.
Yonezawa S, Horinouchi M, Osako M, Kubo M, Takao S, Arimura Y, et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol Int. 1999;49:45–54.CrossRefPubMed
51.
Adsay NV, Merati K, Basturk O, Iacobuzio-Donahue C, Levi E, Cheng JD, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28:839–48.CrossRefPubMed
52.
Furukawa T, Klöppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794–9.CrossRefPubMed
53.
Terris B, Dubois S, Buisine MP, Sauvanet A, Ruszniewski P, Aubert JP, et al. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. J Pathol. 2002;197:632–7.CrossRefPubMed
54.
Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.CrossRefPubMed
55.
Adsay NV, Merati K, Andea A, Sarkar F, Hruban RH, Wilentz RE, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15:1087–95.CrossRefPubMed
56.
Yonezawa S, Taira M, Osako M, Kubo M, Tanaka S, Sakoda K, et al. MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathol Int. 1998;48:319–22.CrossRefPubMed
57.
Gum JR Jr. Mucin genes and the proteins they encode: structure, diversity, and regulation. Am J Respir Cell Mol Biol. 1992;7:557–64.PubMed
58.
Gum JR Jr, Hicks JW, Toribara NW, Siddiki B, Kim YS. Molecular cloning of human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor. J Biol Chem. 1994;269:2440–6.PubMed
59.
Kim YS, Gum JR Jr. Diversity of mucin genes, structure, function, and expression. Gastroenterology. 1995;109:999–1001.CrossRefPubMed
60.
Pigny P, Guyonnet-Duperat V, Hill AS, Pratt WS, Galiegue-Zouitina S, d’Hooge MC, et al. Human mucin genes assigned to 11p15.5: identification and organization of a cluster of genes. Genomics. 1996;38:340–52.CrossRefPubMed
61.
Buisine MP, Janin A, Maunoury V, Audié JP, Delescaut MP, Copin MC, et al. Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma. Gastroenterology. 1996;110:84–91.CrossRefPubMed
62.
Lüttges J, Feyerabend B, Buchelt T, Pacena M, Klöppel G. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 2002;26:466–71.CrossRefPubMed
63.
Terada T, Ohta T, Sasaki M, Nakanuma Y, Kim YS. Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol. 1996;180:160–5.CrossRefPubMed
64.
Zamboni G, Scarpa A, Bogina G, Iacono C, Bassi C, Talamini G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol. 1999;23:410–22.CrossRefPubMed
65.
Nagata K. Analysis of mucins and CD10 expression in pancreatic intraductal neoplasia (in Japanese, with English abstract). Kagoshimadaigaku Igakuzashi (Med J Kagoshima Univ). 2005;57:7–17.
66.
Liver Cancer study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer, the 5th edition, revised version. Tokyo: Kanehara; 2009.
67.
Kim HJ, Kim MH, Lee SK, Yoo KS, Park ET, Lim BC, et al. Mucin-hypersecreting bile duct tumor characterized by a striking homology with an intraductal papillary mucinous tumor (IPMT) of the pancreas. Endoscopy. 2002;32:389–93.CrossRef
68.
Klöppel G, Kosmahl M. Is the intraductal papillary mucinous neoplasia of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm? J Hepatol. 2006;44:249–50.CrossRefPubMed
69.
Sasaki M, Nakanuma Y, Kim YS. Expression of apomucins in the intrahepatic biliary tree in hepatolithiasis differs from that in normal liver and extrahepatic biliary obstruction. Hepatology. 1998;27:54–61.CrossRefPubMed
70.
Sakamoto E, Hayakawa N, Kamiya J, Kondo S, Nagino M, Kanai M, et al. Treatment strategy for mucin-producing intrahepatic cholangiocarcinoma: value of percutaneous transhepatic biliary drainage and cholangioscopy. World J Surg. 1999;23:1038–43. discussion 1043–4.CrossRefPubMed
71.
Sakamoto E, Hayakawa N, Kamiya J, Kondo S, Nagino M, Kanai M, et al. Clinicopathological studies of mucin-producing cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 1997;4:157–62.CrossRef
72.
Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer. 2002;94:62–77.CrossRefPubMed
73.
Ringel J, Lohr M. The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer. 2003;2:1–5.CrossRef
74.
Kim YS, Gum JR Jr, Crawley SC, Deng G, Ho JJ. Mucin gene and antigen expression in biliopancreatic carcinogenesis. Ann Oncol. 1999;10(Suppl 4):51–5.CrossRefPubMed
75.
Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund CA, Makela O. Comparison of a new tumour marker, CA19-9, with alpha-fetoprotein and carcinoembryonic antigen in the patients with upper gastrointestinal diseases. J Clin Pathol. 1984;37:218–22.CrossRefPubMed
76.
Kuusela P, Jalanko H, Roberts P, Sipponen P, Mecklin JP, Pitkänen R, et al. Comparison of CA19–9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer. 1984;49:135–9.PubMed
77.
Ohuchida K, Mizumoto K, Yamada D, Fujii K, Ishikawa N, Konomi H, et al. Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of pancreatic cancer. Int J Cancer. 2006;118:405–11.CrossRefPubMed
78.
Matsuno YK, Saito T, Gotoh M, Narimatsu H, Kameyama A. Supported molecular matrix electrophoresis: a new tool for characterization of glycoproteins. Anal Chem. 2009;81:3816–23.CrossRefPubMed
79.
Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci USA. 1988;85:2320–23.CrossRefPubMed
80.
Shibahara F, Goto M, Nimura Y, Yonezawa S. Pathological features of mucin-producing bile duct tumors: comparison with pancreatic intraductal papillary-mucinous neoplasms (in Japanese with English abstract). Gazou Shindan. 2006;26:595–602.
81.
Shibahara F, Yonezawa S, Nimura Y. Mucin-producing bile duct tumors with comparison to pancreatic IPMN in expression of mucin protein (in Japanese). Tan to Sui. 2006;27:451–7.
Metadata
Title
Significance of mucin expression in pancreatobiliary neoplasms
Authors
Suguru Yonezawa
Michiyo Higashi
Norishige Yamada
Seiya Yokoyama
Masamichi Goto
Publication date
01-03-2010
Publisher
Springer Japan
Published in
Journal of Hepato-Biliary-Pancreatic Sciences / Issue 2/2010
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI
https://doi.org/10.1007/s00534-009-0174-7

Other articles of this Issue 2/2010

Journal of Hepato-Biliary-Pancreatic Sciences 2/2010 Go to the issue

Original article

Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma

Topics

Short- and long-term outcome for living pancreas donors

Original article

Endogenous protease inhibitor uptake within the graft during reperfusion in human liver transplantation

Letter to the editor

Parenchyma-sparing resection for pancreatic neoplasms

Technical note

Laparoscopic-assisted distal pancreatectomy and nephrectomy from a live donor

Original article

Evaluation of cholecystic venous flow using indocyanine green fluorescence angiography